Aurelia Private Equity
Kurhessenstr. 1-3, Frankfurt, Hessen, 60431, Germany
Overview
Aurelia Private Equity is focused on investments in early-stage technology companies in Germany. Intelligent capital is the mainstay of the venture capital business. As a classic early-stage financer and startup consultant, they are interested in fast-growing, technology-oriented companies with great future potential. They see themselves as an entrepreneurial partner who, in addition to capital, also engages in strategic coaching, networking and commercial expertise. AURELIA PRIVATE EQUITY has a partnership-organized structure. Through the participation of all professionals in the decision-making process and in economic success, our actions are characterized by entrepreneurial thinking.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- GILUPI
Participated · Equity · Jan 2011
GILUPI is a Potsdam-based medical device company that has developed the “Nanodetector Cancer 01” to specifically isolate tumor cells from a patient’s circulating blood via antibodies bound on the nanodetector. The isolated cells are intended for analysis of genetic status and detection of genetic aberrations. The company plans to use the newly raised funds mainly to pursue CE certification and subsequent market introduction of its patented detector. That approval was expected in 2011 according to the article. GILUPI was founded in 2006 by CEO Klaus Lücke and operates out of the Science Park of Potsdam-Golm. The company recently completed its third round of funding totaling €3.6M.
Team
No current team members are available.